Kathleen Knights

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and<i>in vitro–in vivo</i>extrapolation of drug clearance and drug-drug interaction potential

John O. Miners, Peter I. Mackenzie, Kathleen Knights · Drug Metabolism Reviews · 2009 · 224 citations

Physiologically-based Pharmacokinetic Modeling, Vivo Clearance, Bioanalysis +16

The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

Andrew Rowland, Kathleen Knights, Peter I. Mackenzie et al. · Drug Metabolism and Disposition · 2008 · 180 citations

Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation

Andrew Rowland, David J. Elliot, Peter I. Mackenzie et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 164 citations

Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity

Kathleen Knights, Arduino A. Mangoni, John O. Miners · Expert Review of Clinical Pharmacology · 2010 · 113 citations

Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation

John O. Miners, Kushari Bowalgaha, David J. Elliot et al. · Drug Metabolism and Disposition · 2011 · 103 citations